ABSTRACT
Magnesium is the fourth most abundant mineral and the second most abundant intracellular divalent cation and has been recognized as a
cofactor for >300 metabolic reactions in the body. Some of the processes in which magnesium is a cofactor include, but are not limited to,
protein synthesis, cellular energy production and storage, reproduction, DNA and RNA synthesis, and stabilizing mitochondrial membranes.
Magnesium also plays a critical role in nerve transmission, cardiac excitability, neuromuscular conduction, muscular contraction, vasomotor
tone, blood pressure, and glucose and insulin metabolism. Because of magnesiums many functions within the body, it plays a major role in
disease prevention and overall health. Low levels of magnesium have been associated with a number of chronic diseases including
migraine headaches, Alzheimers disease, cerebrovascular accident (stroke), hypertension, cardiovascular disease, and type 2 diabetes
mellitus. Good food sources of magnesium include unrefined (whole) grains, spinach, nuts, legumes, and white potatoes (tubers). This review
presents recent research in the areas of magnesium and chronic disease, with the goal of emphasizing magnesiums role in disease prevention and
overall health. Adv. Nutr. 4: 378S383S, 2013.
Introduction
Magnesium is the fourth most abundant mineral and the
second most abundant intracellular divalent cation and
has been recognized as a cofactor for >300 metabolic reactions in the body (1,2). Approximately 50% of magnesium
is in the bone, 50% is in the tissues and organs, and 1% is in
the blood (1,2). Some of the processes in which magnesium
is a cofactor include, but are not limited to, protein synthesis,
cellular energy production and storage, reproduction, DNA
and RNA synthesis, and stabilizing mitochondrial membranes
(36). Magnesium also plays a critical role in maintaining normal nerve and muscle function, cardiac excitability (normal
378 S
heart rhythm), neuromuscular conduction, muscular contraction, vasomotor tone, normal blood pressure, bone integrity,
and glucose and insulin metabolism (316). In this regard,
magnesium deficiency has been associated with a number
of chronic diseases, including migraine headaches, Alzheimers diseases, cerebrovascular accident (stroke), hypertension, cardiovascular disease, and type 2 diabetes
mellitus (1722).
The Dietary Reference Intake for magnesium for adults is
310420 mg/d; magnesium intake is often below these recommendations, particularly as people age (23). Although
magnesium content is high in whole grains and dark, leafy
green vegetables, magnesium is also high in white vegetables
such as white potatoes (2426).
The purpose of this review is to present research in the
area of magnesium and disease. The goal of this paper is
to demonstrate the importance of magnesiums role in disease prevention and overall health.
2013 American Society for Nutrition. Adv. Nutr. 4: 378S383S, 2013; doi:10.3945/an.112.003483.
Food
1/4 cup of wheat bran (57 g)
1 oz of dry roasted almonds (28.4 g)
1/2 cup of frozen, cooked spinach (14.2 g)
1 oz of mixed, dry roasted nuts (28.4 g)
3/4 cup of bran flakes cereal (170 g)
2 tbsp of smooth peanut butter (32 g)
1 medium baked potato with skin
1/2 cup of cooked pinto beans (113 g)
1/2 cup of brown, long-grained cooked rice
(113 g)
1/2 cup of mature seeds, cooked lentils, (113 g)
1 cup of low-fat chocolate milk (234 mL)
1 medium banana
8 fluid oz of low-fat fruit yogurt (234 mL)
1.5 oz of milk chocolate candy bar (43 g)
1 slice of whole-wheat bread,
commercially prepared
1/2 cup of avocado cubed (113 g)
1
89
80
78
64
64
49
48
43
42
36
33
32
32
28
23
22
that leads to muscle contraction, leading to vascular relaxation and thus decreased blood pressure (7).
Dickinson et al. (38) evaluated the effects of magnesium
supplementation for the treatment of hypertension. This
was a meta-analysis using the following inclusion criteria
for studies: 1) randomized, controlled trials of a parallel or
crossover design that compared oral magnesium supplementation with usual care, placebo, or no treatment; 2)
the treatment and follow-up had to be $8 wk in duration,
3) the participants in the studies had to be at least 18 y of
age with a systolic blood pressure $140 mm Hg, and 4)
the researchers had to have reported both systolic and diastolic blood pressure at the end of the follow-up period
(38). The researchers found 12 randomized, controlled trials
that met their criteria, with a total sample size of 545
participants. When all trials were combined, there was no
significant decrease in systolic blood pressure between magnesium supplementation and controls; however, diastolic
blood pressure was significantly decreased. Dickinson et al.
(38) concluded that [i]n view of the poor quality of included trials and the heterogeneity between trials, the evidence in favor of a causal association between magnesium
supplementation and blood pressure reduction is weak
and is probably due to bias. This is because poor quality
studies generally tend to over-estimate the effects of treatment. Larger, longer duration and better quality doubleblind placebo controlled trials are needed to assess the effect
of magnesium supplementation on blood pressure and cardiovascular outcomes.
More recently, Kass et al. (39) conducted a meta-analysis
to assess effect of magnesium supplementation on blood
pressure. They also wanted to establish the characteristics
of trials showing the largest effect size. The primary outcome
measures were systolic blood pressure and diastolic blood
pressure. Of the 141 peer-reviewed articles they identied,
22 trials with 23 sets of data and a total sample size of
1173 were used. The studies ranged from 3 to 24 wk of
follow-up, and all were published before July 2010. The supplemental magnesium dose ranged from 120 to 973 mg/d,
with a mean dose of 410 mg/d used.
When Kass et al. (39) combined their data, the overall effect was 0.32 for systolic blood pressure (95% CI: 0.23, 0.41)
and 0.36 for diastolic blood pressure (95% CI: 0.27, 0.44). A
greater effect was found for interventions in crossover trials:
0.51 for systolic blood pressure and 0.47 for diastolic blood
pressure (39).
In general, Kass et al. (39) reported that higher doses of
magnesium led to greater reductions in blood pressure.
Not all trials that they examined demonstrated a signicant
decrease in blood pressure; however, combining all trials,
there was a 3- to 4-mm Hg decrease in systolic blood pressure and a 2- to 3-mm Hg decrease in diastolic blood pressure. Based on the results of this single meta-analysis (40),
magnesium supplementation appears to achieve a small,
clinically signicant reduction in blood pressure.
Dickinson et al. (39) did not report signicant effects of
magnesium on blood pressure, perhaps because their study
Conclusions
This review highlights areas where magnesium has been
shown to improve symptoms of migraine headaches,
Alzheimers disease, cerebrovascular accident (stroke), hypertension, cardiovascular disease, and type 2 diabetes
mellitus. Although not all researchers have reported improvements or cause-and-effect relationships. there is good
evidence to support the positive influence that magnesium
has on overall health. More research is required, however,
with larger sample sizes to further elucidate magnesiums
effect on health. Longer term, prospective studies using
382S Supplement
Acknowledgments
The sole author had responsibility for all parts of the
manuscript.
Literature Cited
1. Elin RJ. Magnesium: the fifth but forgotten electrolyte. Am J Clin
Pathol. 1994;102:61622.
2. Takaya J, Higashino H, Kobayashi Y. Intracellular magnesium and insulin resistance. Magnes Res. 2004;17:12636.
3. Newhouse IJ, Finstad EW. The effects of magnesium supplementation
on exercise performance. Clin J Sport Med. 2000;10:195200.
4. Bohl CH, Volpe SL. Magnesium and exercise. Crit Rev Food Sci Nutr.
2002;42:53363.
5. Shils ME. Magnesium. In: Shils ME, Olson JA, Shike M, Ross AC, eds.
Modern nutrition in health and disease. 9th ed. Baltimore, MD:
Lippincott Williams & Wilkins; 1999. p. 16992.
6. Chubanov V, Gudermann T, Schlingmann KP. Essential role for
TRPM6 in epithelial magnesium transport and body magnesium homeostasis. Pflugers Arch. 2005;451:22834.
7. Paolisso G, Barbagallo M. Hypertension, diabetes mellitus, and insulin
resistance: the role of intracellular magnesium. Am J Hypertens. 1997;
10:34655.
8. Barbagallo M, Dominguez LJ, Galioto A, Ferlisi A, Cani C, Malfa L,
Pineo A, Busardo A, Paolisso G. Role of magnesium in insulin action,
diabetes and cardio-metabolic syndrome X. Mol Aspects Med. 2003;24:
3952.
9. He K, Liu K, Daviglus ML, Morris SJ, Loria CM, Van Horn L, Jacobs
DR Jr, Savage PJ. Magnesium intake and incidence of metabolic syndrome among young adults. Circulation. 2006;113:167582.
10. Murakami K, Okubo H, Sasaki S. Effect of dietary factors on incidence
of type 2 diabetes: a systematic review of cohort studies. J Nutr Sci
Vitaminol (Tokyo). 2005;51:292310.
11. Guerrero-Romero F, Rodriguez-Moran M. Hypomagnesemia is linked
to low serum HDL-cholesterol irrespective of serum glucose values.
J Diabetes Complications. 2000;14:2726.
12. Gropper SS, Smith JL, Groff JL. Magnesium. Advanced nutrition and
human metabolism. 4th ed. Belmont, CA: Thomson and Wadsworth;
2005.
13. Soltani N, Keshavarz M, Minaii B, Mirershadi F, Asl SZ, Dehpour AR.
Effects of administration of oral magnesium on plasma glucose and
pathological changes in the aorta and pancreas of diabetic rats. Clin
Exp Pharmacol Physiol. 2005;32:60410.
14. McCarty MF. Magnesium may mediate the favorable impact of whole
grains on insulin sensitivity by acting as a mild calcium antagonist.
Med Hypotheses. 2005;64:61927.
15. Lopez-Ridaura R, Willett WC, Rimm EB, Liu S, Stampfer MJ, Manson
JE, Hu FB. Magnesium intake and risk of type 2 diabetes in men and
women. Diabetes Care. 2004;27:13440.
16. Guerrero-Romero F, Rodrguez-Morn M. Low serum magnesium
levels and metabolic syndrome. Acta Diabetol. 2002;39:20913.
17. Kanbay M, Yilmaz MI, Apetrii M, Saglam M, Yaman H, Unal HU,
Gok M, Caglar K, Oguz Y, Yenicesu M, et al. Relationship between
serum magnesium levels and cardiovascular events in chronic kidney
disease patients. Am J Nephrol. 2012;36:22837.
18. Kupetsky-Rincon EA, Uitto J. Magnesium: novel applications in cardiovascular disease. A review of the literature. Ann Nutr Metab. 2012;61:
10210.
19. Kupetsky-Rincon EA, Li Q, Uitto J. Magnesium reduces carotid intimamedia thickness in a mouse model of pseudoxanthoma elasticum: a
novel treatment biomarker. Clin Transl Sci. 2012;5:25964.
20. Reed BN, Zhang S, Marron JS, Montague D. Comparison of intravenous and oral magnesium replacement in hospitalized patients with
cardiovascular disease. Am J Health Syst Pharm. 2012;69:12127.
21. Abbasi IU, Salim-ul-Haque, Kausar MW, Karira KA, Zubaris NA. Correlation of divalent cat ions (Ca++, Mg++) and serum renin in patients
of essential hypertension. J Pak Med Assoc. 2012;62:1348.
22. Barbagallo M, Belvedere M, Di Bella G, Dominguez LJ. Altered ionized
magnesium levels in mild-to-moderate Alzheimers disease. Magnes
Res. 2011;24:S11521.
23. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride.
Washington, DC: National Academies Press; 1997.
24. Subramanian NK, White PJ, Broadley MR, Ramsay G. The threedimensional distribution of minerals in potato tubers. Ann Bot. 2011;
107:68191.
25. Freedman MR, Keast DR. White potatoes, including French fries, contribute shortfall nutrients to childrens and adolescents diets. Nutr Res.
2011;31:2707.
26. U.S. Department of Agriculture, Agricultural Research Service. 2011.
USDA National Nutrient Database for Standard Reference, Release
24. Nutrient Data Laboratory Home Page, http://www.ars.usda.gov/
ba/bhnrc/ndl, retrieved September 16, 2012.
27. Nielsen FH. Magnesium, inflammation, and obesity in chronic disease.
Nutr Rev. 2010;68:33340.
28. Office of Dietary Supplements. Dietary Supplement Fact Sheet: Magnesium. http://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/,
retrieved September 16, 2012
29. Freedman MR, Keast DR. Potatoes, including French fries, contribute
key nutrients to diets of U.S. adults: NHANES 20032006. J Nutr
Ther. 2012;1:111.
30. Arnaud MJ. Update on the assessment of magnesium status. Br J Nutr.
2008;99(Suppl 3):S2436.
31. World Health Organization. Headache disorders. Fact Sheet #277. http:
//www.who.int/mediacentre/factsheets/fs277/en/, retrieved September
16, 2012.
32. Mauskop A. Nonmedication, alternative, and complementary treatments for migraine. Continuum (Minneap Minn). 2012;18:796806.
33. Pringsheim T, Davenport W, Mackie G, Worthington I, Aub M, Christie
SN, Gladstone J, Becker WJ; Canadian Headache Society Prophylactic
Guidelines Development Group. Canadian Headache Society guideline
for migraine prophylaxis. Can J Neurol Sci. 2012; 39(2, Suppl 2)S159.
34. Tarighat Esfanjani A, Mahdavi R, Ebrahimi Mameghani M, Talebi M,
Nikniaz Z, Safaiyan A. The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis. Biol Trace Elem Res. 2012;150:428.
35. Centers for Disease Control and Prevention. FastStats. http://www.cdc.
gov/nchs/fastats/lcod.htm/, retrieved September 16, 2012.
36. Ozawa M, Ninomiya T, Ohara T, Hirakawa Y, Doi Y, Hata J, Uchida K,
Shirota T, Kitazono T, Kiyohara Y. Self-reported dietary intake of
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.